ALNOV Stock Overview
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Novacyt S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.81 |
| 52 Week High | €0.99 |
| 52 Week Low | €0.42 |
| Beta | -1.71 |
| 1 Month Change | 55.47% |
| 3 Month Change | 45.16% |
| 1 Year Change | 42.11% |
| 3 Year Change | -85.96% |
| 5 Year Change | 335.48% |
| Change since IPO | -90.69% |
Recent News & Updates
Recent updates
Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?
Nov 28
We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate
Jul 04Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)
Jan 24With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting
Mar 18With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting
Nov 25Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding
Sep 29Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth
Mar 08Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?
Jan 22
Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)
Dec 15We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability
Nov 19Shareholder Returns
| ALNOV | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 28.6% | 3.1% | 2.2% |
| 1Y | 42.1% | -9.1% | 3.2% |
Return vs Industry: ALNOV exceeded the French Biotechs industry which returned -13% over the past year.
Return vs Market: ALNOV exceeded the French Market which returned 1.3% over the past year.
Price Volatility
| ALNOV volatility | |
|---|---|
| ALNOV Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALNOV's share price has been volatile over the past 3 months.
Volatility Over Time: ALNOV's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 120 | James McCarthy | www.novacyt.com |
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.
Novacyt S.A. Fundamentals Summary
| ALNOV fundamental statistics | |
|---|---|
| Market cap | €57.14m |
| Earnings (TTM) | -€29.42m |
| Revenue (TTM) | €9.15m |
6.2x
P/S Ratio-1.9x
P/E RatioIs ALNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNOV income statement (TTM) | |
|---|---|
| Revenue | UK£7.87m |
| Cost of Revenue | UK£4.84m |
| Gross Profit | UK£3.03m |
| Other Expenses | UK£28.33m |
| Earnings | -UK£25.30m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 38.51% |
| Net Profit Margin | -321.40% |
| Debt/Equity Ratio | 0% |
How did ALNOV perform over the long term?
See historical performance and comparison